P1124: MOSUNETUZUMAB RETREATMENT IS EFFECTIVE AND WELL-TOLERATED IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA

por Cheah, C. Y., Bartlett, N. L., Assouline, S., Schuster, S. J., Seog Kim, W., Shadman, M., Isufi, I., Yin, S., Doral, M. Y., Sit, J., Chen, V., Huang, H., Zhou, M., Wei, M. C., Budde, L. E.
Publicado 2022

Limited role for surveillance PET–CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy

por Cheah, C Y, Hofman, M S, Dickinson, M, Wirth, A, Westerman, D, Harrison, S J, Burbury, K, Wolf, M, Januszewicz, H, Herbert, K, Prince, H M, Carney, D A, Ritchie, D S, Hicks, R J, Seymour, J F
Publicado 2013

P1100: BRUIN MCL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED, BTK INHIBITOR NAÏVE MCL (...

por Eyre, T. A., Shah, N. N., Le Gouill, S., Dreyling, M., Vandenberghe, E., Jurczak, W., Wang, Y., Cheah, C. Y., Gandhi, M., Chay, C., Sharman, J. P., Andorsky, D. J., Yin, M., Balbas, M., Kherani, J., Wang, M. L.
Publicado 2022

A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma

por Cheah, C Y, Herbert, K E, O'Rourke, K, Kennedy, G A, George, A, Fedele, P L, Gilbertson, M, Tan, S Y, Ritchie, D S, Opat, S S, Prince, H M, Dickinson, M, Burbury, K, Wolf, M, Januszewicz, E H, Tam, C S, Westerman, D A, Carney, D A, Harrison, S J, Seymour, J F
Publicado 2014

P1276: DOSE RESPONSE PROFILE OF IGM-2323, A CD20XCD3 IGM BISPECIFIC T CELL ENGAGER, IN TRANSLATIONAL MODELS SUPPORTS PHASE 2 DOSE SELECTION IN NON-HODGKIN’S LYMPHOMA

por Leabman, M. K., Hernandez, G., Ng, C. M., Tang, J., Pandya, D., Hart, K. C., Li, K., Hinton, P. R., So, J., Qazi, I., Cheah, C. Y., Kim, W. S., Budde, E., Gopal, A. K., Manley, T., Takimoto, C. H., Sinclair, A. M., Carroll, S. F., Keyt, B. A., Kotturi, M. F.
Publicado 2022

P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY

por Eyre, T. A., Wang, M. L., Shah, N. N., Alencar, A. J., Gerson, J. N., Patel, M. R., Fakhri, B., Vandenberghe, E., Jurczak, W., Tan, X. N., Lewis, K. L., Fenske, T., Wang, Y., Coombs, C. C., Flinn, I., Lewis, D., Le Gouill, S., Gandhi, M., Chay, C., Palomba, M. L., Woyach, J. A., Pagel, J. M., Lamanna, N., Sharman, J. P., Andorsky, D. J., Cohen, J. B., Barve, M. A., Ghia, P., Yin, M., Zinzani, P. L., Ujjani, C., Koh, Y., Izutsu, K., Lech-Maranda, E., Kherani, J., Tam, C., Sundaram, S., Nair, B., Tsai, D. E., Balbas, M., Mato, A. R., Cheah, C. Y.
Publicado 2022